


Overnight Monitoring Product Accelerated

Following a recent senior management visit to North America, Respi is pleased to advise shareholders that it is accelerating the development of SonoSentry™, its overnight monitoring product. The clinical project lead will be Professor Zahra Moussavi, a globally respected Professor of Biomedical Engineering at the University of Manitoba, Canada. Professor Moussavi has published widely with over 200 publications covering biomedical signal analysis, classification of lung sound and sleep apnea detection.

Asthma symptoms often worsen overnight and a significant 70% of deaths caused by asthma occur during nocturnal hours. Our consumer research confirms that parents are distressed as their children suffer overnight symptoms and want an objective, home based monitoring tool and alarm system to give them peace of mind.

New wireless technology and Respi software platforms will provide this much needed non-invasive, home based monitoring tool. A pilot is expected to be completed towards the end of Q1 of calendar 2017.

SonoSentry™ significantly broadens the company's product offering and the attractiveness of Respi technology to partners. This was confirmed during recent discussions in North America with a potential technology partner.



Leon L'Huillier
Executive Chairman

Ph: 1800 476 632